Valuation
- Market cap
- 102,229,000
- Revenue TTM
- $0
- Net income TTM
- $-6,301,282
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 124,900
- Avg volume
- —
- Day's range
- $11.37 – $12.70
- Shares out
- 8,332,000
- Stochastic %K
- 78%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- $51.67
Company profile
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the d...
Show more
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- (703) 940-9761
- Website
- https://www.retensionpharmaceuticals.com
- Address
- 1104 West Broad Street #1029, Falls Church, United States
Latest news
No headlines yet.